{"ModuleTitle": "Company Description", "CompanyName": "Delcath Systems, Inc.", "Symbol": "DCTH", "Address": "1633 BROADWAY SUITE 22C, NEW YORK, New York, 10019, United States of America", "Phone": "(212) 489-2100", "Industry": "Medical/Dental Instruments", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Unless the context otherwise requires, all references in this Annual Report on\r\nForm 10-K to the \"Company\", \"Delcath\", \"Delcath Systems\", \"we\", \"our\", and \"us\"\r\nrefers to Delcath Systems, Inc., a Delaware corporation, incorporated in August\r\n1988, and all entities included in our consolidated financial statements. Our\r\ncorporate offices are located at 1633 Broadway, Suite 22C, New York, New York\r\n10019. Our telephone number is (212) 489-2100 and our internet address is\r\nwww.delcath.com.\r\n\r\nCompany Overview\r\n\r\nWe are an interventional oncology company focused on the treatment of primary\r\nand metastatic liver cancers. Our lead product candidate, Melphalan\r\nHydrochloride for Injection for use with the Delcath Hepatic Delivery System, or\r\nMelphalan/HDS, is designed to administer high-dose chemotherapy to the liver\r\nwhile controlling systemic exposure and associated side effects.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f25%2f0001564590-20-012846.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "John Purpura", "title": "CEO & Executive VP-Global Head-Operations"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}